227Th-EDTMP: A potential therapeutic agent for bone metastasis

Nuclear Medicine and Biology

Volumn 31, Issue 7, 2004, Pages 901-908

  Washiyama, Kohshin ^a   Amano, Ryohei ^a   Sasaki, Jun ^a   Kinuya, Seigo ^a   Tonami, Norihisa ^a   Shiokawa, Yoshinobu ^b   Mitsugashira, Toshiaki ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

particle emitter; 227Th; Bone metastasis; EDTMP; In vivo generator

Indexed keywords

ANTINEOPLASTIC AGENT; ETHYLENEDIAMINE TETRAMETHYLENEPHOSPHONIC ACID TH 227; RADON; UNCLASSIFIED DRUG; 227TH ETHYLENEDIAMINE TETRAMETHYLENEPHOSPHONIC ACID; 227TH-ETHYLENEDIAMINE-TETRAMETHYLENEPHOSPHONIC ACID; ORGANOMETALLIC COMPOUND; PHOSPHONIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; FEMUR; MALE; MOUSE; NONHUMAN; SOFT TISSUE; ANIMAL; ANTIBODY SPECIFICITY; BONE TUMOR; CHEMISTRY; EVALUATION; FEASIBILITY STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLIC CLEARANCE RATE; METABOLISM; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BONE NEOPLASMS; FEASIBILITY STUDIES; FEMUR; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; PHOSPHONIC ACIDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 4644369303     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.05.001     Document Type: Article

References (29)

1. Mundy G.R. Mechanism of bone metastasis. Cancer. 80:1997;1546-1556
2. Serafini A.N. Therapy of metastatic bone pain. J Nucl Med. 42:2001;895-906
3. Silberstein E.B., Elgazzar A.H., Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 22:1992;17-27
4. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B. 14:1987;223-232
5. Bouchet L.G., Bolch W.E., Goddu S.M., Howell R.W., Rao D.V. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med. 41:2000;682-687
6. Collins C., Eary J.F., Donaldson G., Vernon C., Bush N.E., Petersdorf S., Livingston R.B., Gordon E.E., Chapman C.R., Appelbaum F.R. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 34:1993;1839-1844
7. Atkins H.L., Mausner L.F., Srivastava S.C., Meinken G.E., Straub R.F., Cabahug C.J., Weber D.A., Wong C.T.C., Sacker D.F., Madajewicz S., Park T.L., Meek A.G. Biodistribution of Sn-117m(4+)DTPA for palliative therapy of painful osseous metastases. Radiology. 186:1993;279-283
8. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 40:1999;1197-1203
9. 89Sr in mice. J Nucl Med. 44:2003;252-259
10. 228 (RdTh). Radiat Res. 12:1960;657-671
11. 227Th. Int J Radiat Biol Relat Stud Phys Chem Med. 20:1971;233-243
12. Larsen RH, Henriksen G. Method of Radiotherapy. WIPO Patent WO 02/05859 2002
13. 227Ac und seine Folgeprodukte. Radiochim Acta. 9:1968;181-186
14. 99mTc-labeled radiopharmaceuticals. Eur J Nucl Med. 12:1986;390-393
15. Volkert W.A., Hoffman T.J. Therapeutic radiopharmaceuticals. Chem Rev. 99:1999;2269-2292
16. de Witt G.C., May P.M., Webb J., Hefter G. Biosorption by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent. Biometals. 9:1996;351-361
17. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., Wilson D. Skeletal localization of samarium-153 chelates potential therapeutic bone agents. J Nucl Med. 28:1987;495-504
18. Banerjee S., Samuel G., Kothari K., Unni P.R., Sarma H.D., Pillai M.R.A. Tc-99m and Re-186 complexes of tetraphosphonate ligands and their biodistribution pattern in animal models. Nucl Med Biol. 28:2001;205-213
19. 177Lu-EDTMP a potential therapeutic bone agent. Nucl Med Commun. 19:1998;587-591
20. 105Rh-EDTMP and its bone accumulation. Appl Radiat Isot. 52:2000;211-215
21. 212Bi-EDTMP-synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical. J Label Compd Radiopharm. 34:1994;717-734
22. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., Scheinberg D.A. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 25:1998;1341-1351
23. 224Ra. Int J Radiat Biol Relat Stud Phys Chem Med. 20:1971;27-38
24. Lloyd R.D., Mays C.W., Taylor G.N., Atherton D.R., Bruenger F.W., Jones C.W. Radium-224 retention, distribution, and dosimetry in beagles. Radiat Res. 92:1982;280-295
25. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62:2002;3120-3125
26. 212 in selected bones and soft tissues. Radiat Res. 26:1965;132-145
27. 228Th retention and dosimetry in beagles. Radiat Res. 98:1984;614-628
28. 212Bi-DOTMP an alpha particle emitting bone-seeking agent for targeted radiotherapy. Nucl Med Biol. 24:1997;231-237
29. 225Ra and its daughter nuclides in the neptunium series. Proceedings of the international symposium on bio-trace elements 2002. 2003;173-6